Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma
Blood, vol. 140, pp. 287–288
Abstract
Background: Lenalidomide/dexamethasone has been approved as a standard treatment in multiple myeloma and is applied preferentially in older patients with comorbidities. The addition of daratumumab to this therapy is the best treatment option today for patients who are not transplant eligible. Intensity-reduced high-dose melphalan (MEL140) with autologous transplantation also is an effective treatment option for older patients who are transplant eligible but may not tolerate full dose high-dose melphalan (MEL200). A combination of MEL140 with lenalidomide/dexamethasone potentially could produce a better outcome compared with lenalidomide/dexamethasone alone. Methods: In this trial (DSMM XIII; EudraCT-No: 2008-004083-39) patients of age 60-75 years with newly diagnosed multiple myeloma who had symptomatic and measurable disease were randomly assigned to either (A1) 3 cycles of lenalidomide (25 mg po d1-21/28d) with low-dose dexamethasone (40 mg po d1, d8, d15, d22/28d), followed by stem cell mobilization and then further lenalidomide/dexamethasone cycles until progression or (A2) 3 cycles of lenalidomide/dexamethasone as induction, followed by stem cell mobilization, intensity-reduced high-dose melphalan 140 mg/m2 (MEL140) (single or double) with autologous blood stem cell transplantation and lenalidomide maintenance with 10 mg daily until progression. At randomization, patients were stratified according to age (60-70 years vs 71-75 years) and ISS stage (I, II vs III). The primary endpoint was progression-free survival, and secondary endpoints included safety, response rates and overall survival. Here, we report the long-term outcome. Results: 348 patients were included into the study and 339 patients could be analysed per intention-to-treat (ITT). Patient characteristics were well balanced between treatment arms. For all patients, median age was 68 years (range 60 - 75), 29% were older than 70 years, 36.5% had ISS stage I, 35.6% ISS stage II, and 27.9% ISS stage III. After a median follow-up of 68 months, the median progression-free survival (PFS) was 40 months for A1 (169 patients) and 33 months for A2 (170 patients) (HR 1.16; p=0.19) in the ITT analysis. The median overall survival (OS) was 87 months for A1 and 96 months for A2 (HR 1.04; p=0.81). A prespecified per-protocol (PP) analysis was defined to include patients who received at least 6 months of study treatment (also including patients with progressive disease or death during this time period). In this PP analysis the median PFS was 42 months for A1 (139 patients) and 36 months for A2 (131 patients) (HR 1.15; p=0.27); the median OS was 89 months for A1 and 96 months for A2 (HR 1.01; p=0.96). In arm A2, 115 patients (68%) received one or two transplants. For transplanted patients, median PFS was 40 months and median OS was 114 months. Second primary malignancies (SPMs) were observed in 24 patients in arm A1 (skin 12, solid tumor 11, hematologic 1) and in 20 patients in arm A2 (skin 5, solid tumor 11, hematologic 4). Conclusion: In the intention-to-treat population, the combination of MEL140 with lenalidomide/dexamethasone induction and lenalidomide single agent maintenance was not superior to continuous lenalidomide/dexamethasone treatment. Subgroup analyses with a focus on the role of transplant will be presented at the meeting. Sponsor: Gesellschaft für Medizinische Innovation in der Hämatologie/Onkologie - GMIHO
Authors 38
-
Affiliation as printed
1Clinic of Hematology, Oncology and Stem Cell Transplantation, Muenchen Klinik Schwabing, Munich, Germany
-
Affiliation as printed
2Klinikum Nuernberg, Nuernberg, Germany
-
Affiliation as printed
3Klinikum Bremen Mitte, Bremen, Germany
-
TUM Klinikum · Technical University of Munich
Affiliation as printed
4Department of Medicine III, Klinikum rechts der Isar, Technical University Munich (TUM), Munich, Germany
-
Affiliation as printed
5Asklepios Tumorzentrum Hamburg, AK Altona and AK St. Georg, Hamburg, Germany
-
Affiliation as printed
6Kempten Clinic, Kempten, Germany
-
Affiliation as printed
7Ulm University Hospital, Ulm, Germany
-
Affiliation as printed
8Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
-
University Medical Center Hamburg-Eppendorf
Affiliation as printed
9UKE, Hamburg, Germany
-
University Medical Center Hamburg-Eppendorf
Affiliation as printed
10University Medical Center Hamburg-Eppendorf, Hamburg, Germany
-
University of Freiburg · University Medical Center Freiburg
Affiliation as printed
11Department of Medicine I Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
-
Affiliation as printed
12University Clinic Würzburg, Wuerzburg, Germany
-
Affiliation as printed
13Muenster University Hospital, Muenster, Germany
-
Affiliation as printed
14Med. Klinik III / Poliklinik, Universitätsklinik Erlangen, Erlangen, Germany
-
Affiliation as printed
15Klinikum Oldenburg, Oldenburg, Germany
-
Affiliation as printed
16Stauferklinikum Schwäbisch Gmünd, Mutlangen, Germany
-
University Hospital Regensburg
Affiliation as printed
17University Hospital Regensburg, Regensburg, Germany
-
University Hospital Regensburg
Affiliation as printed
17University Hospital Regensburg, Regensburg, Germany
-
Affiliation as printed
18HSK Wiesbaden, Wiesbaden, Germany
-
Affiliation as printed
19Helios Hospital Berlin Buch, Berlin, Germany
-
Affiliation as printed
20Helios Klinikum Berlin-Buch, Berlin, Germany
-
Universitätsmedizin Göttingen · University of Göttingen
Affiliation as printed
21Universitätsklinikum Göttingen, Göttingen, Germany
-
University Hospital Schleswig-Holstein
Affiliation as printed
22University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
-
Affiliation as printed
23Onkologie Ravensburg, Ravensburg, Germany
-
Affiliation as printed
23Onkologie Ravensburg, Ravensburg, Germany
-
Affiliation as printed
24Diakonie Hospital Stuttgart, Stuttgart, Germany
-
Universitätsklinikum Aachen · RWTH Aachen University
Affiliation as printed
25Uniklinik RWTH Aachen, Aachen, Germany
-
Affiliation as printed
26Klinikum Landshut, Landshut, Germany
-
Affiliation as printed
27University Hospital Frankfurt, Frankfurt, Germany
-
Affiliation as printed
28Department for Internal Medicine 3, St. Marien-Krankenhaus Siegen, Siegen, Germany
-
Gemeinschaftsklinikum Mittelrhein
Affiliation as printed
29Gemeinschaftsklinikum Mittelrhein, Koblenz, Germany
-
Affiliation as printed
30Red Cross Hospital Munich, Munich, Germany
-
Affiliation as printed
30Red Cross Hospital Munich, Munich, Germany
-
Affiliation as printed
32University Greifswald, Greifswald, Germany
-
Affiliation as printed
33Medical Centre, Robert-Bosch-Hospital,, Stuttgart, Germany
-
Affiliation as printed
34Hämatologisch-Onkologische Gemeinschaftspraxis Pasing, Munich, Germany
-
Affiliation as printed
35CCRC Cancer Clinical Research Consulting, Düsseldorf, Germany
-
University of Würzburg · Universitätsklinikum Würzburg
Affiliation as printed
36Universitaetsklinikum Wuerzburg, Med. Klinik und Poliklinik II, Wuerzburg, Germany
Cited by 17 stored of 17
17 results
No patents citing this paper on Lens.org (checked 2026-10-06).